Table 3 Differences in baseline demographic and clinical characteristics in primary prevention patients between the Improve SCA registry and previous large-scale non-Asian-Pacific registries from the 2000s
| Â | MADIT II 2002 [8] | DEFINITE 2004 [9] | COMPANION | SCD-HeFT 2005 [12] | DANISH 2016 [13] | EU-CERT-ICD 2020 [14] | Improve SCA 2020 |
|---|---|---|---|---|---|---|---|
N | 1232 | 458 | 1520 | 2521 | 1116 | 2247 | 2696 |
N. of patients with defibrillator | 742 | 229 | 595 | 829 | 556 | 1516 | 1399 |
Median follow-up time (months) | 20 | 29 | 16 | 45.5 | 67.6 | 28.8 ± 13.2 | 21.6 ± 10.2 |
Age (years) | 64 | 58.3 | 66 | 60 | 63 | 62.4 | 61 |
Male (%) | 84.4 | 71.2 | 67 | 77 | 72.6 | 81.8 | 76.7 |
NICM (%) | 0 | 100 | 45 | 47 | 100 | 35 | 68.5 |
Country income level LMI/UMI/HIÂ (%) | 0/0/100 | 0/0/100 | 0/0/100 | 0/0/100 | 0/0/100 | 0/? /Mainly HI | 21.2/50.1/28.7 |
Ethnicity (%) | |||||||
 Black or African (%) | - | 25.8 | - | 16.9 | - | - | 0.5 |
 White (%) | 87 | 67.2 | Mainly White | 76.6 | Mainly White | Mainly White | 6.9 |
 Asian (%) | - | 0.2 | - | - | - | - | 89.8 |
Medical history | |||||||
 NYHA Class, I/II/III/IV (%) | 36.5/34.6/24.2/4.6 | 21.6/57.4/21/0 | -/-/86/14 | -/69/31/- | -/53/45/1 | 60.5(I/II)/39.5(III/IV) | 1.2/47/51.7/0 |
 Hypertension (%) | 53 | - | - | 55.6 | 31.2 | - | 38.7 |
 Diabetes (%) | 34.98 | 22.9 | 41 | 30.4 | 19 | 30.3 | 30.5 |
 Myocardial infarction (%) | 100 | 0 | - | 45 | 0 | - | 35.1 |
 CRT implanted (%) | 0 | 0 | 79.7 | 0 | 58 | 0 | 25.5 |
 NSVT (%) | - | 90.6 | - | 23.1 | - | - | 29.7 |
 LVEF mean (%) | 23.2 | 21.4 | 21.2 | 25 | 25 | 28 | 27 |
 QRS duration (ms) | 120 | 115.1 | 160 | 112 | 146 | 105.4 ± 17.7 | 118 |
 LBBB(%) | 18.6 | 19.7 | 70.8 | - | 53.6 | - | 24.1 |
Medicine | |||||||
 Beta blockers (%) | 62 | 84.9 | 68 | 69 | 92 | 94.3 | 75.7 |
 ACEI/ARB (%) | 89 | 96.7 | 90 | 94 | 97 | 91.2 | 71.2 |
 Diuretics (%) | 75.6 | 86.7 |  > 94 | 82 | - | 72.2 | 84 |